279 programming-"the"-"DAAD"-"IMPRS-ML"-"FEMTO-ST"-"U.S"-"https:" positions at University of Sheffield
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
will take place on 18th or 19th December. This will consist ofan interview. We plan to let candidates know if they have progressed to the selection stage on the week commencingMonday 8th December. If you
-
process will take place on w/c 15th December 2025. This will consist of an interview, and presentation. We plan to let candidates know if they have progressed to the selection stage on the week commencing 8
-
decision making on programme design, approval and delivery. Oversight of the processes that support administration of the curriculum, including leading on programme and module development, amendment and
-
of students’ work. Apply programme and module learning outcomes to teaching undertaken and liaise with module leaders to ensure the delivery of high-quality teaching that fulfils School objectives. Carry out
-
Overview An opportunity has arisen to recruit a Clinical Trial Manager to support an established program of clinical studies in the area of pulmonary hypertension (PH) and heart failure. You will be
-
intellectual property associated with CAP and help develop a regulatory strategy and commercialisation plan. You will aid in the establishment of value proposition and identify potential customers for CAP
-
Pillar of our University Vision and Strategic Plan . Key areas of focus for the team include; delivering excellent outcomes from the Staff Wellbeing Services, creating a disability and neuro-inclusive
-
is anticipated that the selection process will take place in November. This will consist ofan interview, tour of the building and discussion with the research group. We plan to let candidates know
-
programme, enabling them to develop novel experimental characterisation techniques to study the flow behaviour of DFCs, and subsequently develop a constitutive material model to be incorporated into a virtual
-
for the treatment of amyotrophic lateral sclerosis (ALS). This project is a hit to lead program for the development of modulators to target non-coding triple-helix RNA (NEAT 1). The successful candidate will play a